Primary Source Monitoring: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for…
Pharmacy Compounding Advisory Committee discusses new bulk substances.
What changed & why it matters
Med Spa Radar recorded a regulatory change at the federal level, in the GLP-1 Compounding category.
This change is tracked for its potential impact on med-spa and injectable practice — what a practice may do, who may perform it, and from whom product may be sourced.
- Type
- Primary Source Monitoring
- Jurisdiction
- Federal
- Category
- GLP-1 Compounding
What this means for your specific practice — the exact step to take, the deadline to calendar, or the supplier detail to check — is in the member "what to do" below. This page is the free record of what changed and why it matters.
What to do
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get the full “what to do” on every alert — in one daily email, for your states. Become a member →
Primary Source Monitoring · primary source ↗
Related alerts
- FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061,…
- FDA Warning Letter: K.C. Pharmaceuticals, Inc (Drugs)
- FDA recall (Class II): Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …
- FDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
- FDA recall (Class II): Wegovy (Semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
- FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
Monitoring, not legal advice.